Analytical issues of serum free light chain assays and the relative performance of polyclonal and monoclonal based reagents

Clinical Chemistry and Laboratory Medicine

Volumn 54, Issue 6, 2016, Pages 997-1003

  Carr Smith, Hugh D ^a   Jenner, Ellen L ^a   Evans, Josie A R ^a   Harding, Stephen J ^a  

^a Binding Site Group Ltd   (United Kingdom)

Author keywords

antigen excess; Freelite; lot to lot variation; N latex; non linearity

Indexed keywords

ANTIGEN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; REAGENT; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN;

ASSAY; CLINICAL PRACTICE; GAMMOPATHY; HUMAN; IMMUNOASSAY; LABORATORY; LIGHT CHAIN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; ACUTE KIDNEY INJURY; BLOOD; COMPLICATION; DEVICES; IMMUNOLOGY; MULTIPLE MYELOMA; PROCEDURES; URINE;

ACUTE KIDNEY INJURY; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; MULTIPLE MYELOMA; PRACTICE GUIDELINES AS TOPIC;

EID: 84969780624     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2015-1068     Document Type: Review

References (32)

1. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003;361:489-91.
2. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001;97:2900-2.
3. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78-84.
4. Fuchida SI, Okano A, Hatsuse M, Murakami S, Haruyama H, Itoh S, et al. Serial measurement of free light chain detects poor response to therapy early in three patients with multiple myeloma who have measurable M-proteins. Int J Hematol 2012;96:664-8.
5. Brioli A, Giles H, Pawlyn C, Campbell J, Kaiser M, Melchor L, et al. Serum free light chain evaluation as a marker for the impact of intra-clonal heterogeneity on the progression and treatment resistance in multiple myeloma. Blood 2014;123:3414-9.
6. Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol 2008;9:11.
7. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111:785-9.
8. Rajkumar SV, Kyle RA, Therneau TM, Melton LJ, III, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106:812-7.
9. Rajkumar SV, Dimopolous MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538-48.
10. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-24.
11. Tate JR, Mollee P, Dimeski G, Carter AC, Gill D. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin Chim Acta 2007;376:30-6.
12. Murata K, Clark RJ, Lockington KS, Tostrud LJ, Greipp PR, Katzmann JA. Sharply increased serum free light-chain concentrations after treatment for multiple myeloma. Clin Chem 2010;56:16-8.
13. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-80.
14. Cavalcanti E, Barchiesi V, Cuomo M, Di Paola F, Morabito F, Cavalcanti S. A particular case of lambda chain multiple myeloma. Biochimica Clinica 2013;37:428-30.
15. Hoedemakers RM, Pruijt JF, Hol S, Teunissen E, Martens H, Stam P, et al. Clinical comparison of new monoclonal antibodybased nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis. Clin Chem Lab Med 2011;50:489-95.
16. Lock R, Saleem R, Roberts E, Wallage M, Pesce T, Rowbottom A, et al. A multicentre study comparing two methods for serum free light chain analysis. Ann Clin Biochem 2013;50:255-61.
17. Pretorius CJ, Klingberg S, Tate J, Wilgen U, Ungerer JP. Evaluation of the N Latex FLC free light chain assay on the Siemens BN analyser: precision, agreement, linearity and variation between reagent lots. Ann Clin Biochem 2012;49(Pt 5):450-5.
18. Schneider N, Wynckel A, Kolb B, Sablon E, Gillery P, Maquart FX. [Comparative analysis of immunoglobulin free light chains quantification by Freelite (The Binding Site) and N Latex FLC (Siemens) methods]. Ann Biol Clin (Paris) 2013;71:13-9.
19. Kubicki T, Dytfeld D, Baszczuk A, Lewandowski K, Komarnicki M. Polyclonal based serum free light chains assessment better than monoclonal based test characterizes disease activity in patients with multiple myeloma. Presented at Lymphoma and Myeloma 2015;P5a.
20. van Velzen JF, van den Blink D, Bloem AC. Inability of a monoclonal anti-light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry. Cytometry B Clin Cytom 2013;84:30-2.
21. Jacobs JF, Hoedemakers RM, Teunissen E, van der Molen RG, Te VH. Effect of sample dilution on two free light chain nephelometric assays. Clin Chim Acta 2012;413:1708-9.
22. Sharrod-Cole H, Matters D, Showell P, Harding S. Serum free light chain assessments: Comparison of precision and linearity. Biochmica Clinica 2013;37(SS):T390a.
23. Bosmann M, Kossler J, Stolz H, Walter U, Knop S, Steigerwald U. Detection of serum free light chains: the problem with antigen excess. Clin Chem Lab Med 2010;48:1419-22.
24. Vercammen M, Meirlaen P, Broodtaerts L, Broek IV, Bossuyt X. Effect of sample dilution on serum free light chain concentration by immunonephelometric assay. Clin Chim Acta 2011;412: 1798-804.
25. Burden JM, Matters DJ, Carr-Smith HD, Young P, Harding SJ. Comparison of Freelite and N Latex FLC utilising diagnostically relevant samples. Clin Chem 2012;58(Suppl 10):C44a.
26. Harding SJ, Popat R, Berlanga O, Sharrod H, Cavenagh J, Oakervee H. Comparison of the analytical performance of polyclonal and monoclonal antibody based FLC assays in refractory multiple myeloma patients. Clin Chem 2013;59 (Suppl 10):A22a.
27. te Velthuis H, Knop I, Stam P, van den Broek M, Bos HK, Hol S, et al. N Latex FLC-new monoclonal high-performance assays for the determination of free light chain kappa and lambda. Clin Chem Lab Med 2011;49:1323-32.
28. Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008;73:1282-8.
29. Hutchison CA, Cockwell P, Cook M. Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy. BMC Clin Pathol 2012;12:12.
30. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008;3:1684-90.
31. Jacobs JF, Hoedemakers RM, Teunissen E, Te VH. N Latex FLC serum free light-chain assays in patients with renal impairment. Clin Chem Lab Med 2014;52:853-9.
32. Tate J, Bazeley S, Klingberg S, Pretorius CJ, Hawley C, Mollee P. Comparison of the Freelite and N Latex serum free light chain (FLC) assays in chronic kidney disease. Clin Biochem Rev 2012;33(Supplement):P53a.